- Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibitionAmy D Guertin
Department of Oncology, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, USA
Cancer Cell Int 12:45. 2012..abstract:..
- Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapyAmy D Guertin
Oncology Biology, Merck Research Laboratories, Boston, MA, USA
Mol Cancer Ther 12:1442-52. 2013..Our findings provide rationale for WEE1 inhibition as a potent anticancer therapy independent of a genotoxic partner and suggest that low PKMYT1 expression could serve as an enrichment biomarker for MK-1775 sensitivity...